Featured Research

from universities, journals, and other organizations

Immunotherapy Slows Disease Progression And Lowers PSA Levels In Some Men With Prostate Cancer, UCSF Study Finds

Date:
December 13, 2000
Source:
University Of California, San Francisco
Summary:
A novel therapy that employs the immune system to attack and kill prostate cancer cells has been found to slow disease progression in some men and decrease levels of prostate specific antigen (PSA), a protein in the blood that often indicates prostate cancer, a UCSF study has found.

A novel therapy that employs the immune system to attack and kill prostate cancer cells has been found to slow disease progression in some men and decrease levels of prostate specific antigen (PSA), a protein in the blood that often indicates prostate cancer, a UCSF study has found.

The study of 31 men involved collecting patients' dendritic cells from their bloodstream and mixing them in a test tube with a synthetic version of prostatic acid phosphatase (PAP), an antigen found on the surface of most prostate cancer cells. Dendreon Corporation in Seattle Washington prepared the therapy, called Provenge, made of synthetic PAP combined with dendritic cells. The modified dendritic cells were then infused back into the patient with the hope that they would help trigger the patient's immune system to kill prostate cancer cells throughout the body, said study author Eric Small, MD, associate professor of medicine and member of the UCSF Comprehensive Cancer Center's Urologic Oncology program.

The results will be published in the December 1 issue of the Journal of Clinical Oncology.

Dendritic cells are an integral part of the immune system. They scavenge foreign material, such as bacteria and viruses, and then interact with another important component of the immune system, lymphocytes, bringing this foreign material to the lymphocytes' attention. The lymphocytes then jump into action and circulate through the body, destroying the foreign substance. The goal of the study was to see if these modified dendritic cells would be able to train the lymphocytes to recognize cells with PAP on their surface as a foreign substance and kill those cells. The men in the study received an infusion of dendritic cells once a month for three months.

The Phase I/II study enrolled men with advanced prostate cancer --defined as tumors spreading beyond the prostate to other parts of the body and no longer responding to conventional hormone therapies. The median age of the participants was 69 years old, with a range from 48 to 83. Twenty of the men had a strong immune response to PAP after treatment. For these men, time until their disease progressed, or became worse, was 34 weeks compared to 13 weeks for those patients who had weaker immune responses. In addition, three patients had a greater than 50 percent decrease in PSA. Three more patients had a 25 percent to 49 percent decrease in PSA. A PSA decrease of more than 50 percent has been accepted by most researchers as a reasonable indication of anticancer activity, according to the study.

Small said the results of this study were encouraging. "It really shows the immune system can be manipulated and made to recognize prostate cancer," he said. "This trial shows we can break tolerance to the antigen. Immunologically, we always thought we couldn't do that in prostate cancer."

While other studies have shown immunotherapy to have some benefit in melanoma and kidney cancer, this study is one of the first to demonstrate an effect in prostate cancer, Small said.

"Immune therapy for prostate cancer has not historically been viewed with much enthusiasm. This is because it was believed that the immune system, for whatever reason, did not recognize prostate tumors as foreign and therefore they did not illicit an immune response," Small said. "As it turns out, that isn't the case. Apparently, the immune system was just not being adequately stimulated to attack the cancer."

The therapy was well tolerated by patients, with mild fever being the most common side effect.

The trial lays the groundwork for future research of this therapy, including using it in patients with less extensive disease and possibly in combination with other therapeutic agents. Small is principal investigator of a Phase III trial of Provenge that is enrolling about 240 men with advance disease at multiple sites nationwide. "This trial opens up an huge arena of further study," Small said.

Prostate cancer is the most common cancer, excluding nonmelanoma skin cancers, in American men, according to the American Cancer Society. It is the second leading cause of cancer deaths in men, exceeded only by lung cancer. Physicians initially treat advanced disease by prescribing hormones to deprive a man's body of testosterone, which fuels prostate cancer growth. However, all patients ultimately develop hormone independent disease, meaning the cancer progresses despite lowering testosterone. The median survival for this group of patients is about a year, according to the study. The American Cancer Society estimates 180,400 new cases of prostate cancer will be diagnosed this year in the U.S. and about 31,900 men will die of this disease.

Other UCSF study authors are David M. Reese, MD, assistant clinical professor of medicine and Paige Fratesi, research assistant. Authors from Dendreon are George Strang, clinical data systems management analyst; Reiner Laus, MD, vice president, immunology; Madhusudan V. Peshwa, PhD, vice president, process science and Frank H. Valone, MD, senior vice president, medical & regulatory affairs

Dendreon funded this study and is funding the Phase III trial.


Story Source:

The above story is based on materials provided by University Of California, San Francisco. Note: Materials may be edited for content and length.


Cite This Page:

University Of California, San Francisco. "Immunotherapy Slows Disease Progression And Lowers PSA Levels In Some Men With Prostate Cancer, UCSF Study Finds." ScienceDaily. ScienceDaily, 13 December 2000. <www.sciencedaily.com/releases/2000/12/001204072100.htm>.
University Of California, San Francisco. (2000, December 13). Immunotherapy Slows Disease Progression And Lowers PSA Levels In Some Men With Prostate Cancer, UCSF Study Finds. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2000/12/001204072100.htm
University Of California, San Francisco. "Immunotherapy Slows Disease Progression And Lowers PSA Levels In Some Men With Prostate Cancer, UCSF Study Finds." ScienceDaily. www.sciencedaily.com/releases/2000/12/001204072100.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Newsy (July 30, 2014) The Peace Corps is one of several U.S.-based organizations to pull workers out of West Africa because of the Ebola outbreak. Video provided by Newsy
Powered by NewsLook.com
Weather Kills 2K A Year, But Storms Aren't The Main Offender

Weather Kills 2K A Year, But Storms Aren't The Main Offender

Newsy (July 30, 2014) Health officials say 2,000 deaths occur each year in the U.S. due to weather, but it's excessive heat and cold that claim the most lives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins